Study of Cilostazol and Ginkgo Biloba Extract to Improve Thinking in Older Adults with Type 2 Diabetes

What this Trial Is About

Researchers are investigating the potential cognitive benefits of a combination therapy using cilostazol 200 mg and ginkgo biloba extract 160 mg in older adults with type 2 diabetes mellitus. This study is a phase 3, randomized trial focusing on whether this treatment can help prevent or reduce cognitive decline, given the higher risk of dementia in people with diabetes. The study aims to provide important data for future treatments targeting cognitive impairment in this population. Participants will be randomly assigned to receive either the combination therapy or a placebo. The active treatment involves taking a sustained-release tablet once daily containing both cilostazol and ginkgo biloba extract. The placebo group will take a similar-looking tablet without the active ingredients. This treatment phase lasts for 6 months. During the study, participants will undergo regular assessments including cognitive tests such as the Mini-Mental State Examination MMSE, Korean Dementia Screening Questionnaire, Montreal Cognitive Assessment, and Global Deterioration Scale. Health-related quality of life will also be measured using the Short Form-36 survey. Researchers will monitor changes in these measures from the start to the end of the 6-month period to evaluate cognitive improvement and safety.

Cilostazol-Ginkgo for Cognitive Function in Elderly Diabetes